Education
About Us
Working with TipRanks
Follow Us
NovaBridge Biosciences (NBP)
NASDAQ:NBP
NBP Stock Chart & Stats
$3.11
--
Market closed
$3.11
--
Day’s Range― - ―
52-Week Range$0.60 - $6.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)537.89K
Market Cap
$368.93M
Enterprise Value$867.89M
Total Cash (Recent Filing)$1.63B
Total Debt (Recent Filing)$23.32M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Apr 01, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding115,119,490
10 Day Avg. Volume529,785
30 Day Avg. Volume537,895
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market Cap2.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.98
Forecast
1Y Price Target
$9.00Price Target Upside189.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Givastomig Phase 1b EfficacyRobust Phase 1b efficacy and a planned global randomized Phase 2 materially de-risk clinical development for givastomig. Durable impact: if Phase 2 confirms benefit, NovaBridge could secure a best‑in‑class position in CLDN18.2 gastric cancer, enabling partnerships and non-dilutive funding sources.
Ragistomig Improved Dosing And SafetyA safer, effective Q6W regimen enhances ragistomig's viability in combinations and later‑stage trials. Long-term, improved tolerability broadens potential indications, lowers development risk in combo regimens, and strengthens partner interest for global development and commercialization.
Low Leverage / Positive EquityA low-debt balance sheet gives NovaBridge financial flexibility to fund near-term trials and absorb R&D volatility without heavy interest burden. Structurally, modest leverage improves options for orderly financing, partnerships, or asset-centric transactions versus highly leveraged peers.
Bears Say
Revenue Collapsed To ZeroZero product revenue means the company remains pre-commercial and wholly reliant on development milestones and external financing. Over months to years this limits organic funding, increases execution risk for clinical programs, and reduces visibility into self-sustaining operations.
Persistent Negative Cash FlowSustained negative operating and free cash flow depletes liquidity and shortens runway absent material financing or partnerships. This structurally raises likelihood of dilutive financing, delays to trials or cuts to programs, and higher counterparty risk for long‑term collaborations.
Balance Sheet Vulnerability HistoryPrior negative equity and continued losses indicate the balance sheet can deteriorate quickly under stress. Over the medium term, this raises the probability of restructuring, asset sales, or highly dilutive capital raises that would impair strategic continuity and partner confidence.
NovaBridge Biosciences News
NBP FAQ
What was NovaBridge Biosciences’s price range in the past 12 months?
NovaBridge Biosciences lowest stock price was $0.59 and its highest was $6.79 in the past 12 months.
What is NovaBridge Biosciences’s market cap?
NovaBridge Biosciences’s market cap is $368.93M.
When is NovaBridge Biosciences’s upcoming earnings report date?
NovaBridge Biosciences’s upcoming earnings report date is Apr 01, 2026 which is in 27 days.
How were NovaBridge Biosciences’s earnings last quarter?
NovaBridge Biosciences released its earnings results on Nov 13, 2025. The company reported -$0.025 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.068.
Is NovaBridge Biosciences overvalued?
According to Wall Street analysts NovaBridge Biosciences’s price is currently Undervalued.
Does NovaBridge Biosciences pay dividends?
NovaBridge Biosciences does not currently pay dividends.
What is NovaBridge Biosciences’s EPS estimate?
NovaBridge Biosciences’s EPS estimate is -0.04.
How many shares outstanding does NovaBridge Biosciences have?
NovaBridge Biosciences has 115,119,490 shares outstanding.
What happened to NovaBridge Biosciences’s price movement after its last earnings report?
NovaBridge Biosciences reported an EPS of -$0.025 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went down -1.185%.
Which hedge fund is a major shareholder of NovaBridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Company Description
NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(189.39% Upside)
Ownership Overview
―
Insiders
0.05%
Mutual Funds
12.83% Other Institutional Investors
86.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---